4 results
Primary outcome:The effect of Pyridostigmine (cholinesterase inhibitor) on inflammatory signs as pain, temperature and swelling of the extremity measured according to TREND protocol (appendix 1).Pain is measured according to VAS scale, temperature,…
to investigate the effect and efficacy of pyridostigmine on muscle strength and fatiquabillity in patients with SMA.
Objective: to investigate if Ulipristal is non-inferior to GnRH in terms of intra-operative blood-loss (primary outcome), surgical time, surgical ease, complications, quality of life and costs.
To assess the proportion of patients who are alive without disease progression at 6 months based on local investigator assessment per RECIST v1.1 in cohort A and cohort B 13-03-2019: new cohort added (3 cohorts now)